The past year hasn't been kind to the stocks featured in this article.
Each has tumbled to their lowest points in 12 months, leaving investors to decide whether they're witnessing fire sales or falling knives.
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.
Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
Zymeworks rises after Ziihera shows significant PFS and OS benefits in a Phase 3 trial, supporting plans for regulatory filings and guideline submissions.
Initial and continuing jobless claims rose slightly year over year, with adjusted levels remaining near their highest since 2021. The data points to a neutral but weakly expanding economy, with trends largely unchanged
According to a Reuters report, rather than seeking Lukoil’s entire global asset base, Chevron is considering only the operations that overlap with its existing business.
Tariffs are generally inflationary because they increase the cost of importing goods for U.S. businesses, which then have to decide to absorb the higher costs or pass them along to consumers.
Last month, I recommended shorting 10% out-of-the-money PLTR put options for a 4.24% one-month yield. PLTR closed with no assignment to buy shares. A 3.5% yield is possible for a 9.8% one-month OTM short put play.
Elon Musk’s vision for Tesla’s Cybertruck reflects his blend of futurism, functionality, and survivalist design philosophy rooted in bold practicality.
Ford partners with Amazon to sell certified used cars on e-commerce site, following Hyundai's lead. Customers can browse, finance, and pick up at dealers.
The S&P 500 Index ($SPX ) (SPY ) today is down -0.49%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.50%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.46%. December E-mini S&P futures (ESZ25 ) are down -0.24%, and Decembe...
HF Sinclair (DINO) stands out with strong technical momentum and recently set new 52-week highs. Shares maintain a 100% “Buy” opinion from Barchart. DINO has gained 32.44% over the past year and nearly 60% in the year to date. Fundamentals are solid...
BitMine Immersion Technologies Inc. (NYSE:BMNR) is down almost 6% on Monday, despite announcing that its crypto and cash holdings have grown to $11.8 billion in
QUBT gained over 13% after reporting 280% revenue growth to $384,000, turning profitable, and unveiling its new Neurawave photonics platform backed by $1.5 billion in funding.
Shares of computer hardware and IT solutions company Dell (NYSE:DELL) fell 6.9% in the morning session after Morgan Stanley issued a double downgrade on the stock, cutting its rating from 'Overweight' to 'Underweight' and slashing its price target.
Shares of restaurant technology provider PAR Technology (NYSE:PAR) fell 3.3% in the morning session after investors continued to react to its recent third-quarter earnings report, where the company missed profit expectations even as it beat on revenue.
Shares of e-commerce and gaming company Sea (NYSE:SE) jumped 3.9% in the morning session after the company's board of directors authorized a $1 billion share repurchase program, its first ever, and Phillip Securities upgraded the stock's rating.
Shares of human capital management provider Alight (NYSE:ALIT) fell 3.7% in the morning session after investors continued to the company's recent quarterly earnings report, which missed analyst expectations on both profit and revenue.
Shares of memory chips maker Micron (NYSE:MU)
jumped 1.2% in the morning session after Rosenblatt raised its price target for the stock to $300, contributing to the positive momentum.
Shares of luxury electric car manufacturer Lucid (NASDAQ:LCID) fell 7.4% in the morning session after Stifel lowered its price target on the stock, citing concerns about the company's need for more capital.
Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ)
jumped 18.3% in the morning session after the company announced positive top-line results from its Phase 3 HERIZON-GEA-01 trial for its cancer drug, Ziihera.
